KEY TAKEAWAYS
- The study aimed to investigate the trends in morbidity and mortality among patients with OC & liver metastases and assess the impact of various treatments on cancer-specific survival.
- The primary endpoint was to determine OS & CSS.
- Researchers noticed a declining trend in morbidity and mortality rates for patients with OC and liver metastases.
Na Li and the team aimed to examine the trends in morbidity and mortality among patients with ovarian cancer (OC) with liver metastases and investigate the impact of different treatments on both overall survival (OS) and cancer-specific survival (CSS). Notably, only surgery and chemotherapy conferred survival benefits to patients.
They performed an inclusive analysis involving 2,925 patients with OC with liver metastases from the Surveillance, Epidemiology, and End Results (SEER) database spanning 2010-2019. The primary endpoint focused on OS and CSS. Trend analysis was conducted to assess the incidence, OS, and CSS rates of liver metastases in OC.
Univariate and multivariate COX proportional risk models were utilized to explore the association between different treatment methods and OS, while univariate and multivariate competing risk models were employed to evaluate the impact of treatment methods on CSS.
At the end of follow-up, about 689 patients were alive. The OS and CSS rates were 76.44% and 72.99%, respectively. A significant decreasing trend was observed in the incidence (AAPC) = -2.3, 95% CI: -3.9, -0.7], all-cause mortality (AAPC = -12.8, 95% CI: -15.6, -9.9), and specific mortality (AAPC = -13.0, 95% CI: -16.1, -9.8) rate of liver metastases in OC.
After adjusting for all confounding factors, only receiving surgery was associated with improved OS (HR = 0.39, 95% CI: 0.31-0.48) and CSS (HR = 0.37, 95% CI: 0.30-0.47). Chemotherapy was also identified as a protective factor for OS (HR = 0.33, 95% CI: 0.30-0.37) and CSS (HR = 0.44, 95% CI: 0.39-0.50) in patients with OC.
Subgroup analyses revealed that surgery and chemotherapy remained significant protective factors for OS and CSS for patients without other distant metastases, with distant metastases to the bone, lung, brain, or other organs, with bone metastasis, and with lung metastasis.
The study concluded that a notable downward trend exists in morbidity and mortality rates among patients with liver metastases originating from OC. Only the receipt of surgery and chemotherapy as treatment modalities was associated with survival benefits for patients.
The study was sponsored by the Jilin Provincial Science and Technology Department Fund, Liaoning Provincial Science and Technology Talents, Natural Science Foundation, and Jilin Provincial Department of Education Fund.
Source: https://pubmed.ncbi.nlm.nih.gov/38635517/
Li N, Jin S, Wu J, et al. (2024). “Effect of different treatment modalities on ovarian cancer patients with liver metastases: A retrospective cohort study based on SEER.” PLoS One. 2024 Apr 18;19(4):e0299504. doi: 10.1371/journal.pone.0299504. PMID: 38635517; PMCID: PMC11025763.
